115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan

Background

Trifluridine/tipiracil (lonsurf) and regorafenib are standard of treatment in patients with chemo-refractory metastatic colorectal cancer (mCRC). Our study aimed to investigate the impact of sidedness on survival in patients with mCRC treated with lonsurf or regorafenib.

Methods

Patients who were diagnosed with mCRC and treated with lonsurf or regorafenib between 2015 and 2022 were retrospectively identified from Taiwan National Health Insurance Research Database and Taiwan Cancer Registry. Propensity score matching was used to reduce the selection bias. The oncologic outcomes were presented with time to treatment failure (TTF) and overall survival (OS).

Results

A total of 4665 patients were identified. After matching, 752 patients were analyzed for outcomes comparison, including 376 patients in each group. In general, median TTF and OS were 1.9 months versus 2.0 months (p = 0.701)and 9.1 months versus 7.0 months (p = 0.008) in lonsurf and regorafenib, respectively. Patients were stratified by sidedness, including 297 left side mCRC in each group and 79 right side mCRC in each group. For patients with left side colon, median TTF and OS were 1.9 months versus 2.0 months (p = 0.178) and 10.2 months versus 7.8 months (p = 0.006) in lonsurf and regorafenib, respectively, while for patients with right side colon, median TTF and OS were 1.8 months versus 1.8 months (p = 0.390) and 7.8 months versus 6.0 months (p = 0.011) in lonsurf and regorafenib, respectively.

Conclusions

Lonsurf provided a longer survival over regorafenib in mCRC patients regardless of sidedness of primary tumor location.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.